Dyadic International (DYAI) Competitors $1.04 -0.02 (-1.42%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. EDIT, GLSI, TARA, SCPH, LYEL, TNXP, FATE, THTX, ALEC, and ACOGShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), Lyell Immunopharma (LYEL), Tonix Pharmaceuticals (TNXP), Fate Therapeutics (FATE), Theratechnologies (THTX), Alector (ALEC), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Editas Medicine Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Tonix Pharmaceuticals Fate Therapeutics Theratechnologies Alector Alpha Cognition Editas Medicine (NASDAQ:EDIT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Is EDIT or DYAI more profitable? Dyadic International has a net margin of -188.09% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% Dyadic International -188.09%-149.16%-59.81% Does the MarketBeat Community favor EDIT or DYAI? Editas Medicine received 156 more outperform votes than Dyadic International when rated by MarketBeat users. However, 64.40% of users gave Dyadic International an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31753.46% Underperform Votes27646.54% Dyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Does the media prefer EDIT or DYAI? In the previous week, Editas Medicine had 10 more articles in the media than Dyadic International. MarketBeat recorded 13 mentions for Editas Medicine and 3 mentions for Dyadic International. Editas Medicine's average media sentiment score of 0.65 beat Dyadic International's score of -0.28 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of EDIT or DYAI? 71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 2.1% of Editas Medicine shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, EDIT or DYAI? Dyadic International has lower revenue, but higher earnings than Editas Medicine. Dyadic International is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$35.84M3.50-$153.22M-$3.04-0.49Dyadic International$3.50M8.87-$6.80M-$0.20-5.15 Which has more risk and volatility, EDIT or DYAI? Editas Medicine has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Do analysts prefer EDIT or DYAI? Editas Medicine presently has a consensus target price of $5.36, indicating a potential upside of 257.58%. Dyadic International has a consensus target price of $6.00, indicating a potential upside of 482.52%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.29Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEditas Medicine beats Dyadic International on 11 of the 19 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.99M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-4.4830.5026.8419.71Price / Sales8.87400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book5.153.286.794.50Net Income-$6.80M-$72.17M$3.23B$248.18M7 Day Performance-0.96%4.28%4.07%1.14%1 Month Performance-17.60%7.62%12.52%15.18%1 Year Performance-38.30%-28.15%16.83%6.55% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.2941 of 5 stars$1.03-2.8%$6.00+482.5%-34.3%$30.99M$3.50M-4.487Positive NewsEarnings ReportEDITEditas Medicine4.2699 of 5 stars$1.54+6.2%$5.73+271.9%-70.3%$128.91M$32.31M-0.60230Positive NewsGap UpGLSIGreenwich LifeSciences1.337 of 5 stars$9.58+1.6%$39.00+307.1%-21.3%$127.17MN/A-11.973Positive NewsEarnings ReportTARAProtara Therapeutics2.1845 of 5 stars$3.27+0.9%$20.40+523.9%+16.4%$126.15MN/A-1.1630Positive NewsGap UpSCPHscPharmaceuticals4.1728 of 5 stars$2.48+1.6%$14.00+464.5%-18.6%$124.70M$36.33M-1.3130Earnings ReportAnalyst RevisionLYELLyell Immunopharma2.9698 of 5 stars$0.42+5.4%$1.00+137.2%-84.2%$124.52M$61,000.00-0.53270Positive NewsGap DownTNXPTonix Pharmaceuticals3.3964 of 5 stars$19.19+1.9%$585.00+2,948.5%-95.1%$123.49M$10.09M0.0050Gap UpFATEFate Therapeutics4.3788 of 5 stars$1.07+2.9%$4.60+329.9%-68.0%$122.63M$13.63M-0.65550Positive NewsGap UpTHTXTheratechnologiesN/A$2.61-0.4%N/A+108.8%$120.01M$88.67M-26.10140ALECAlector3.7824 of 5 stars$1.20+2.6%$4.00+233.3%-74.7%$119.99M$88.34M-0.71270News CoveragePositive NewsGap DownACOGAlpha Cognition1.6757 of 5 stars$7.45+0.3%$20.00+168.5%N/A$119.35MN/A-2.91N/AEarnings Report Related Companies and Tools Related Companies Editas Medicine Alternatives Greenwich LifeSciences Alternatives Protara Therapeutics Alternatives scPharmaceuticals Alternatives Lyell Immunopharma Alternatives Tonix Pharmaceuticals Alternatives Fate Therapeutics Alternatives Theratechnologies Alternatives Alector Alternatives Alpha Cognition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
